Clinical trial · Interventional
Combination Chemotherapy and Radiation Therapy in Treating Young Patients With Hodgkin's Lymphoma
Optimising Therapy for Boys With Hodgkin's Lymphoma and Quality Assurance of Therapy for Girls With Hodgkin's Lymphoma Until Start of a New Prospective Trial for Hodgkin's Lymphoma in Childhood and Adolescence
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high-energy x-rays to kill cancer cells. Giving combination chemotherapy together with radiation therapy may kill more cancer cells. PURPOSE: This phase II trial is studying the side effects and how well giving combination chemotherapy together with radiation therapy works in treating young patients with Hodgkin's lymphoma.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Lymphoma | Lymphoma | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (8)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| cyclophosphamide | Drug | Cyclophosphamide | ALIAS |
| dacarbazine | Drug | Dacarbazine | ALIAS |
| doxorubicin hydrochloride | Drug | Doxorubicin | ALIAS |
| etoposide | Drug | Etoposide | ALIAS |
| prednisone | Drug | Prednisone | ALIAS |
| procarbazine hydrochloride | Drug | Procarbazine | ALIAS |
| radiation therapy | Radiation | — | UNRESOLVED |
| vincristine sulfate | Drug | Vincristine | ALIAS |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (3)
- measure
- Safety and efficacy
- measure
- Reduction of gonadotoxicity
- measure
- Quality assurance
Eligibility
Eligibility (as posted)
- Sex
- All
- Maximum age
- 17 Years
Show eligibility criteria text
DISEASE CHARACTERISTICS:
* Diagnosis of classic Hodgkin's lymphoma (HL)
* Intermediate or advanced disease, including the following stages:
* Stage I
* Stage IIA, IIB, IIE, or IIBE
* Stage IIIA or IIIBE
* Stage IV
PATIENT CHARACTERISTICS:
* No other concurrent malignancies
* No severe concurrent diseases (e.g., immune deficiency syndrome)
PRIOR CONCURRENT THERAPY:
* No prior chemotherapy or radiotherapy
* Pre-phase therapy for large mediastinal tumor allowedReferences
Publications (0)
Data not yet available